TransDigm Group Incorporated (NYSE:TDG) Thursday revealed a strong quarter in Q4 ended September 30, featuring better-than-expected net sales and adjusted earnings, after the commercial aftermarket "recovered nicely" in the second half of its fiscal year. The manufacturer of aircraft components earned $125.4 million, or $2.21 per share, on an adjusted basis, up 25.7% from last year's adjusted earnings of $99.7 million, or $1.75 per share. Analysts were expecting adjusted EPS of only $2.02, according to Capital IQ. Net income attributable to shareholders was $114.3 million, or $1.91 per share, compared with a net loss of $84 million, or $.20 per share, in the comparable quarter a year ago.Net sales for the quarter rose 19% to $642.2 million, trouncing the Capital IQ consensus of $628.29 million. Organic net sales grew approximately 10.1%, of which approximately two-thirds was attributable to strong commercial aftermarket sales. CEO W. Nicholas Howley commented: "Fiscal 2014 was a good year for TransDigm Group Incorporated (NYSE:TDG). The commercial aftermarket recovered nicely in the second half of our fiscal year, and perhaps even ran a little ahead of itself in the fourth quarter." Given a strong performance in the quarter and in the year, the company is now expecting adjusted EPS of $8.03 to $8.29 on net sales of $2.51 billion to $2.55 billion. TDG is trading near the high end of 52-week range $143.19 - $198.29.Click here for a free comprehensive Trend Analysis ReportRXi Pharmaceuticals Corp (NASDAQ:RXII), a biotechnology company, announced a narrower Q3 loss from the same period a year ago as revenues decreased year-over-year. RXi Pharmaceuticals Corp (NASDAQ:RXII) reported a Q3 loss of $0.17 per share, narrower than the loss of $0.30 per share reported in Q3 2013 and narrower than the loss of $0.22 predicted by analysts. Total revenues of $16,000 were down from $92,000 in Q3 2013 and missed analyst projections of $20,000 for the quarter.Research and development expenses for the quarter were $1.5 million, up from $1.2 million in Q3 2013. The increase of $0.3 million is primarily attributable to an increase of $0.2 million during the quarter related to preclinical ophthalmology studies in support of an investigational new drug application for an ocular indication. Shares of RXII are at $1.89 within a 52-week range of $1.64 - $6.84.Click here for a free comprehensive Trend Analysis ReportVertex Energy Inc (NASDAQ:VTNR) reported a Q3 loss that wasn't expected by analysts due to both a decline in the market and costs associated with the turnaround and maintenance of its Thermal Chemical Extraction Process plant. Vertex Energy Inc (NASDAQ:VTNR), the company that recycles industrial waste streams and provides other environmental services said it had a loss of $1.93 million or $0.08 per diluted share compared to a profit of $2.33 million or $0.12 a year ago and below expectations of a profit of $0.06 per share. Revenue jumped to $76.9 million from $46.8 million. Analysts had expected sales of $73.5 million."The third quarter was impacted by both strategic internal decisions as well as the decline in the market," Benjamin Cowart said in a statement. "We took an important step in the quarter to complete some long-term maintenance work on our TCEP plant. This turnaround at TCEP affected our third quarter production there. In addition, we cooperated with the State of Louisiana to complete some necessary stack testing as part of a permit process."Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
